Inventor · disambiguated record
Zhongguo Wang
Also filed as: WANG ZHONGGUO
58 granted patents·17 pending applications·458 citations·filing 1999–2024
99Inventor score
Top patents by PatentIndex Score
75 records- 0198US10550098B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2020·17 cites·25 claims
- 0298US10414752B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·19 cites·20 claims
- 0398US9834539B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Dec 5, 2017·28 cites·108 claims
- 0498US9624175B2Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Apr 18, 2017·25 cites·39 claims
- 0598US9624216B2Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Apr 18, 2017·26 cites·74 claims
- 0697US11980611B2Treating sickle cell disease with a pyruvate kinase R activating compoundNOVO NORDISK HEALTHCARE AG·Filed 2022·Granted May 14, 2024·3 cites·4 claims
- 0797US11844787B2Activating pyruvate kinase RNOVO NORDISK HEALTHCARE AG·Filed 2021·Granted Dec 19, 2023·5 cites·4 claims
- 0897US11649242B2Pyrrolopyrrole compositions as pyruvate kinase (PKR) activatorsFORMA THERAPEUTICS INC·Filed 2021·Granted May 16, 2023·5 cites·4 claims
- 0997US11498913B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2020·Granted Nov 15, 2022·4 cites·18 claims
- 1097US11071725B2Activating pyruvate kinase RFORMA THERAPEUTICS INC·Filed 2020·Granted Jul 27, 2021·8 cites·21 claims
- 1197US10675274B2Activating pyruvate kinase RFORMA THERAPEUTICS INC·Filed 2019·Granted Jun 9, 2020·12 cites·13 claims
- 1297US9771349B2Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Sep 26, 2017·27 cites·68 claims
- 1396US11299484B2Inhibiting fatty acid synthase (FASN)FORMA THERAPEUTICS INC·Filed 2020·Granted Apr 12, 2022·3 cites·22 claims
- 1496US11014927B2Pyrrolopyrrole compositions as pyruvate kinase (PKR) activatorsFORMA THERAPEUTICS INC·Filed 2018·Granted May 25, 2021·6 cites·3 claims
- 1596US10005734B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Jun 26, 2018·25 cites·75 claims
- 1696US9815817B2Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Nov 14, 2017·24 cites·48 claims
- 1795US10889567B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Jan 12, 2021·5 cites·21 claims
- 1895US10772874B2Compounds and compositions for the inhibition of NAMPTFORMA TM LLC·Filed 2019·Granted Sep 15, 2020·6 cites·11 claims
- 1995US10280150B2Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitorsFORMA TM2 INC·Filed 2017·Granted May 7, 2019·19 cites·2 claims
- 2095US10266495B2Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA TM2 INC·Filed 2018·Granted Apr 23, 2019·19 cites·9 claims
- 2195US10253015B2Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA TM2 INC·Filed 2018·Granted Apr 9, 2019·20 cites·12 claims
- 2294US10294206B2Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA TM2 INC·Filed 2015·Granted May 21, 2019·7 cites·16 claims
- 2394US9676721B2Compounds and compositions for the inhibition of NAMPTBAIR KENNETH W·Filed 2011·Granted Jun 13, 2017·33 cites·7 claims
- 2493US10647695B2Compounds and compositions for the inhibition of NAMPTFORMA TM LLC·Filed 2019·Granted May 12, 2020·5 cites·7 claims
- 2593US10272072B2Compounds and compositions for the inhibition of NAMPTFORMA TM LLC·Filed 2016·Granted Apr 30, 2019·11 cites·19 claims
- 2692US10577329B2Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Mar 3, 2020·4 cites·20 claims
- 2792US9169209B2Compounds and compositions for the inhibition of NAMPTBAIR KENNETH W·Filed 2011·Granted Oct 27, 2015·25 cites·22 claims
- 2891US11547701B2Compounds and compositions for the inhibition of NAMPTVALO HEALTH INC·Filed 2020·Granted Jan 10, 2023·2 cites·11 claims
- 2991US11279687B2Compounds and compositions for the inhibition of NAMPTVALO HEALTH INC·Filed 2020·Granted Mar 22, 2022·2 cites·9 claims
- 3091US10456382B2Compounds and compositions for the inhibition of NAMPTFORMA TM LLC·Filed 2018·Granted Oct 29, 2019·7 cites·20 claims
- 3191US10407419B2Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Sep 10, 2019·5 cites·5 claims
- 3291US10329275B2Compounds and compositions for the inhibition of NAMPTFORMA TM LLC·Filed 2018·Granted Jun 25, 2019·8 cites·10 claims
- 3390US9555039B2Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)BAIR KENNETH W·Filed 2011·Granted Jan 31, 2017·13 cites·19 claims
- 3490US2024391922A1Pyrrolopyrrole compositions as pyruvate kinase (pkr) activatorsNovo Nordisk Heathcare AG·Filed 2024·Application pending·0 cites
- 3588US12071440B2Pyrrolopyrrole compositions as pyruvate kinase (PKR) activatorsNOVO NORDISK HEALTHCARE AG·Filed 2023·Granted Aug 27, 2024·0 cites·4 claims
- 3688US10550099B2Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2020·4 cites·15 claims
- 3787US12275715B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2023·Granted Apr 15, 2025·0 cites·23 claims
- 3887US10807976B2Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Oct 20, 2020·2 cites·18 claims
- 3985US11479564B2Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)VALO HEALTH INC·Filed 2020·Granted Oct 25, 2022·1 cites·7 claims
- 4084US12128035B2Activating pyruvate kinase RNOVO NORDISK HEALTHCARE AG·Filed 2022·Granted Oct 29, 2024·1 cites·21 claims
- 4183US12336981B2Compounds and compositions for the inhibition of NAMPTVALO HEALTH INC·Filed 2022·Granted Jun 24, 2025·0 cites·11 claims
- 4283US10889592B2Thienopyrazine carboxamides as ubiquitin-specific protease inhibitorsVALO EARLY DISCOVERY INC·Filed 2017·Granted Jan 12, 2021·2 cites·28 claims
- 4383US10399980B2Purinones as ubiquitin-specific protease 1 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 3, 2019·2 cites·11 claims
- 4483US10189841B2Purinones as ubiquitin-specific protease 1 inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Jan 29, 2019·3 cites·11 claims
- 4583US2023125739A1Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4682US11524966B1Carboxamides as ubiquitin-specific protease inhibitorsVALO EARLY DISCOVERY INC·Filed 2018·Granted Dec 13, 2022·2 cites·15 claims
- 4782US10875848B2Inhibiting fatty acid synthase (FASN)FORMA THERAPEUTICS INC·Filed 2019·Granted Dec 29, 2020·1 cites·30 claims
- 4881US11161848B2Purinones as ubiquitin-specific protease 1 inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Nov 2, 2021·1 cites·26 claims
- 4981US10696692B2Amido-benzyl sulfone and sulfoxide derivatesFORMA TM LLC·Filed 2013·Granted Jun 30, 2020·6 cites·4 claims
- 5080US10913753B2Thienopyridine carboxamides as ubiquitin-specific protease inhibitorsFORMA THERAPEUTICS INC·Filed 2017·Granted Feb 9, 2021·2 cites·20 claims
Showing the top 50 of 75 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Zhongguo Wang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →